| Apr 30 |
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)
|
| Apr 9 |
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
|
| Apr 2 |
Scynexis: Update Following Restructuring Of GSK Deal
|
| Mar 28 |
SCYNEXIS GAAP EPS of $1.39 misses by $0.14, revenue of $140.14M misses by $1.84M
|
| Mar 28 |
SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
|
| Jan 30 |
SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference
|
| Jan 29 |
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 against Mucormycosis at the 11th Advances Against Aspergillosis and Mucormycosis Conference
|
| Jan 5 |
SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Advances Against Aspergillosis and Mucormycosis Conference, January 25 – 27, in Milan, Italy
|
| Jan 3 |
GSK revises Scynexis licensing deal for antifungal agent
|
| Dec 18 |
Scynexis: Stock Has Been Punished Enough: GSK Partnership, Future Revenue Potential And 2-Year Cash Runway Warrant A 'Buy'
|
